TY - JOUR
T1 - COVID 19 pandemic challenges and their management
T2 - A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues
AU - Mohapatra, Sradhanjali
AU - Ayash Kumar, P.
AU - Farooq, Uzma
AU - Jain, Pooja
AU - Khan, Rahmuddin
AU - Hassan, Nazia
AU - Shamim, Athar
AU - Javed Ansari, Mohammad
AU - Alalaiwe, Ahmed S.
AU - Aldawsari, Mohammed F.
AU - Aamir Mirza, Mohd
AU - Iqbal, Zeenat
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/7
Y1 - 2022/7
N2 - The SARS‐CoV‐2 (COVID 19) paroxysm is a dominant health exigency that caused significant distress, affecting physical and mental health. Increased mortality, a stressed healthcare system, financial crisis, isolation, and new living and working styles enhanced societal commiseration leading to poor health outcomes. Though people try to maintain good physical health but unfortunately the mental affliction is still ignored. Poor psychological health has emerged as a burgeoning social issue and demands attention. Henceforth, the fundamental objective of this review article is to collate information about COVID-linked physical and psychological agony in diverse population groups with related symptoms and accessible diagnosis techniques. Recent studies have unraveled the fragile mental states of people who have either contracted COVID 19 or had near and dear ones falling prey to it. The impact of the epidemic on the human mind both in short and long-term, with possible risk and preventive factors together with suggested solutions for maintaining good health have also been discussed here. It also enlists the available medications, vaccines and investigational research in the form of patents and clinical trials. This article can be taken as an updated information sheet for COVID 19, accompanied by its management techniques with special emphasis on coping strategies for mental health. Further, it may also assist the policymakers to devise approaches that could enable the public to overcome the pandemic-driven adversity not only in the given situation but also futuristically.
AB - The SARS‐CoV‐2 (COVID 19) paroxysm is a dominant health exigency that caused significant distress, affecting physical and mental health. Increased mortality, a stressed healthcare system, financial crisis, isolation, and new living and working styles enhanced societal commiseration leading to poor health outcomes. Though people try to maintain good physical health but unfortunately the mental affliction is still ignored. Poor psychological health has emerged as a burgeoning social issue and demands attention. Henceforth, the fundamental objective of this review article is to collate information about COVID-linked physical and psychological agony in diverse population groups with related symptoms and accessible diagnosis techniques. Recent studies have unraveled the fragile mental states of people who have either contracted COVID 19 or had near and dear ones falling prey to it. The impact of the epidemic on the human mind both in short and long-term, with possible risk and preventive factors together with suggested solutions for maintaining good health have also been discussed here. It also enlists the available medications, vaccines and investigational research in the form of patents and clinical trials. This article can be taken as an updated information sheet for COVID 19, accompanied by its management techniques with special emphasis on coping strategies for mental health. Further, it may also assist the policymakers to devise approaches that could enable the public to overcome the pandemic-driven adversity not only in the given situation but also futuristically.
KW - Clinical trial
KW - COVID 19
KW - Medication
KW - Mental health
KW - Patents
KW - Physical health
KW - SARS‐CoV‐2
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85131531581&partnerID=8YFLogxK
U2 - 10.1016/j.jsps.2022.05.004
DO - 10.1016/j.jsps.2022.05.004
M3 - Review article
AN - SCOPUS:85131531581
SN - 1319-0164
VL - 30
SP - 879
EP - 905
JO - Saudi Pharmaceutical Journal
JF - Saudi Pharmaceutical Journal
IS - 7
ER -